

CLAIMS

1. A vaccine composition comprising:
- (a) a *Salmonella typhi* purified Vi polysaccharide and
- 5 (b) at least one other antigen
- wherein the vaccine components are stable and do not interfere with each other.
2. A vaccine composition as claimed in claim 1 in which the other antigen is a hepatitis A antigen.
- 10 3. A vaccine composition according to claim 1 or claim 2 which additionally comprises an adjuvant.
4. A vaccine composition according to claim 3 wherein the adjuvant is a
- 15 preferential stimulator of TH1-cell response.
5. A vaccine composition according to any preceding claim which additionally comprises a carrier.
- 20 6. A vaccine composition according to claim 4 in which the preferential stimulator of TH1-cell response is selected from the group of adjuvants comprising: 3D-MPL, 3D-MPL wherein the size of the particles of 3D-MPL is preferably about or less than 100nm, QS21, a mixture of QS21 and cholesterol, or a combination of two or more of said adjuvants.
- 25 7. A vaccine composition according to claim 6 in which the preferential stimulator of TH1-cell response is 3D-MPL.
8. A vaccine composition according to any one of claims 1 to 7 in which the
- 30 Hepatitis A antigen is derived from the HM-175 strain.
9. A vaccine composition according to any one of claims 1 to 8 in which an hepatitis B antigen is additionally present.

10. A vaccine composition as defined in claim 9 in which the Hepatitis B antigen is hepatitis surface antigen.
- 5 11. A vaccine composition according to claim 5 in which the carrier is selected from the group comprising aluminium hydroxide, aluminium phosphate and an oil in water emulsion.
12. A vaccine composition according to claim 11 in which the carrier is aluminium
10 hydroxide.
13. A vaccine composition according to any one of claims 1 to 12 which additionally comprises a dengue antigen.
- 15 14. A vaccine composition according to claim 13 in which the dengue antigen is selected from the group comprising envelope (E) glycoprotein proteins, truncated envelope glycoprotein proteins and Dengue viral proteins.
15. A vaccine composition according to any one of claims 1 to 14 which
20 additionally comprises an hepatitis E antigen.
16. A vaccine composition according to claim 15 in which the hepatitis E antigen is SAR 55.
- 25 17. A method of manufacture of Vi polysaccharide wherein the method comprises:
a. fermentation of a preculture of *S. typhi*;
b. extraction and purification of the Vi polysaccharide in the absence of phenol; and
c. vacuum drying and storage.
- 30 18. *S. typhi* Vi polysaccharide produced by the method of claim 17.

AI: Add claims
19-41